Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Pd-l1 expression gene signatures: MerckRecent Research Landscape

Low response rates to immunotherapy create wasted clinical costs and patient risk. These innovations utilize specific genetic and receptor signatures to gate patient selection for PD-1 antagonist regimens.

What technical problems is Merck addressing in Pd-l1 expression gene signatures?

Insufficient immune checkpoint response

(29)evidences

Low patient response to monotherapy and systemic administration limitations. Overcoming these barriers improves clinical outcomes across diverse tumor types.

Unpredictable immunotherapy response rates

(4)evidences

Clinical inability to identify which patients will benefit from PD-1 antagonists or combination therapies. Precise patient stratification prevents ineffective treatments and improves survival outcomes.